Mirvetuximab (M9346A) is a novel folate receptor alpha (FRalpha) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRalpha-positive cancers.
Purity:
>95%
CAS Number:
[1453084-36-0]
Target:
Antifolate|||ADC Antibody
* VAT and and shipping costs not included. Errors and price changes excepted